- Dimerix (DXB) has awarded $1M from the Medical Research Future Fund (MRFF) Biomedical Translation Bridge (BTB) program
- Dimerix will use the funding to develop and evaluate its DMX-200 drug candidate as a new treatment for respiratory complications derived from COVID-19
- The therapy has included in the global REMAP-CAP study for patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19
- The drug therapy also aimed at reducing damage from inflammatory immune cells by blocking their signalling and limiting movement
- Encouragingly, global experts see DMX-200 as a compelling treatment option to limit inflammation in the lungs
- Dimerix shares are currently trading 7.86 per cent higher for 75.5 cents
